[Pharmacokinetics and metabolism of cyclosporin; drug interactions].
The pharmacokinetic properties of cyclosporine and mainly its absorption and hepatic elimination can vary in each patient in relation to the subject's individual characteristics (inter-subject variability), as well as in an individual patient during his treatment because of clinical episodes or drug interactions (intra-subject variabilities). Therefore, it appears compulsory to follow regularly cyclosporine blood levels or even to characterise each subject following a dose-test during the initiation of treatment, in order to adapt an individual posology aiming to minimise as far as possible the risk of nephrotoxicity.
Le Bigot
J F
JF
Laboratoires Sandoz, Rueil-Malmaison.
Lavene
D
D
Kiechel
J R
JR
D000284:Administration, Oral; D000818:Animals; D001711:Biotransformation; D003524:Cyclosporins / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*; D004285:Dogs; D004347:Drug Interactions; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D007275:Injections, Intravenous; D007654:Ketoconazole / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008775:Methylprednisolone / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D014018:Tissue Distribution
D003524:Cyclosporins; D004917:Erythromycin; D007654:Ketoconazole; D008775:Methylprednisolone
Pharmacocinétique et métabolisme de la cyclosporine; interactions médicamenteuses.